Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (161-170 of 344) with videos related to

Pageof 35
Sort By:
Japanese Journal of Clinical Oncology|February 9, 2021
Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trialMasaaki Noguchi, Kohei Shitara, Akihito Kawazoe, et al.
The Lancet. Gastroenterology & Hepatology|January 28, 2021
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trialAkihito Kawazoe, Takayuki Ando, Hisashi Hosaka, et al.
International Journal of Clinical Oncology|March 26, 2011
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancerAyako Mizota, Kohei Shitara, Chihiro Kondo, et al.
Cancer Medicine|December 23, 2023
Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trialsHiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant SettingZev A Wainberg, Jipan Xie, Adriana Valderrama, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2022
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancerNicole M Myer, Kohei Shitara, Hyun C Chung, et al.
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 23, 2011
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancerKohei Shitara, Keitaro Matsuo, Ayako Mizota, et al.
BMC Cancer|October 28, 2009
Association between an 8q24 locus and the risk of colorectal cancer in JapaneseKeitaro Matsuo, Takeshi Suzuki, Hidemi Ito, et al.
Japanese Journal of Clinical Oncology|July 14, 2021
Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancerKeiko Minashi, Takeshi Yamada, Hisashi Hosaka, et al.
Pageof 35

Showing results (161-170 of 344) with videos related to

Sort By:
Pageof 35
Japanese Journal of Clinical Oncology|February 9, 2021
Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trialMasaaki Noguchi, Kohei Shitara, Akihito Kawazoe, et al.
The Lancet. Gastroenterology & Hepatology|January 28, 2021
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trialAkihito Kawazoe, Takayuki Ando, Hisashi Hosaka, et al.
International Journal of Clinical Oncology|March 26, 2011
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancerAyako Mizota, Kohei Shitara, Chihiro Kondo, et al.
Cancer Medicine|December 23, 2023
Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trialsHiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant SettingZev A Wainberg, Jipan Xie, Adriana Valderrama, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2022
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancerNicole M Myer, Kohei Shitara, Hyun C Chung, et al.
JNCI Cancer Spectrum|June 2, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curseYu Yang Soon, Katrin Sjoquist, Ian C Marschner, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 23, 2011
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancerKohei Shitara, Keitaro Matsuo, Ayako Mizota, et al.
BMC Cancer|October 28, 2009
Association between an 8q24 locus and the risk of colorectal cancer in JapaneseKeitaro Matsuo, Takeshi Suzuki, Hidemi Ito, et al.
Japanese Journal of Clinical Oncology|July 14, 2021
Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancerKeiko Minashi, Takeshi Yamada, Hisashi Hosaka, et al.
Pageof 35